Literature DB >> 30007441

Administration of plasmacytoid dendritic cell-stimulative lactic acid bacteria enhances antigen-specific immune responses.

Hiroaki Suzuki1, Kenta Jounai2, Konomi Ohshio3, Toshio Fujii3, Daisuke Fujiwara4.   

Abstract

Lactic acid bacteria (LAB) have been reported to have beneficial effects on protective immunity against viruses and pathogenic bacteria by activating innate immune cells such as dendritic cells (DC) or macrophages. However, little is known about whether LAB contributes to antigen-specific immune responses. Because plasmacytoid DC (pDC) links innate and acquired immunity, here we investigated whether the pDC-stimulative LAB, Lactococcus lactis strain Plasma (LC-Plasma), influences antigen-specific immune responses. In in vitro co-culture experiments, LC-Plasma enhanced the expression of MHC class I and II, and CD80 and CD86 on both pDC and conventional DC, and this enhancement was abolished by treatment with a Toll-like receptor 9 antagonist. A subsequent in vitro study showed that LC-Plasma increased antigen-specific T cell responses via DC activation. In mice, oral administration of LC-Plasma in combination with intraperitoneal antigen administration enhanced the percentage of antigen-specific CD8+ T cells and the amount of antigen-specific IgG. Furthermore, continuous intake of LC-Plasma increased T helper 1 responses, which contribute to antigen-specific cellular and humoral immune responses. Taken together, these results reveal that the oral intake of pDC-stimulative LAB enhances antigen-specific immune responses.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antigen-specific immune responses; Dendritic cells; Lactic acid bacteria; T cell immunity

Mesh:

Substances:

Year:  2018        PMID: 30007441     DOI: 10.1016/j.bbrc.2018.07.042

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild COVID-19: protocol for an exploratory, multicentre, double-blinded, randomised controlled trial (PLATEAU study).

Authors:  Kazuko Yamamoto; Naoki Hosogaya; Tsuyoshi Inoue; Kenta Jounai; Ryohei Tsuji; Daisuke Fujiwara; Katsunori Yanagihara; Koichi Izumikawa; Hiroshi Mukae
Journal:  BMJ Open       Date:  2022-09-14       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.